Physician

Bruce Ira Kappel, MD

According to 2025 Medicare claims, Bruce Kappel, MD (NPI: 1336120211) practices hematology/oncology in the Nassau County-Suffolk County, NY market, with the plurality of this provider's patient population coming from Nassau, NY. This provider's primary affiliated billing organization is MEDICAL CARE OF QUEENS, PC (NPI: 1225683840; TIN: 474377679) and primary practice location at 11797-2036.

Kappel's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,072 traditional Medicare patients, billed 113,809 HCPCS/CPT codes, and received $1,747,194 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 924 prescription claims across 165 beneficiaries totaling $1,705,600 in drug costs, led by Promacta (Eltrombopag Olamine). DME data shows 73 claims. Open Payments data shows 9 records totaling $195. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	795	162,461	$1,853,721
2016	1,197	180,871	$2,090,543
2017	1,083	191,631	$2,387,749
2018	1,043	183,704	$2,846,656
2019	1,073	211,884	$2,712,141
2020	1,077	178,258	$2,493,176
2021	1,072	190,799	$2,686,287
2022	1,048	161,045	$2,238,226
2023	1,066	121,436	$1,642,398
2024	1,072	113,809	$1,747,194

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	118	609	$767,279
2016	129	692	$1,347,920
2017	129	801	$1,666,487
2018	148	897	$2,085,799
2019	157	998	$2,214,953
2020	156	895	$2,042,947
2021	134	836	$2,050,504
2022	136	821	$1,870,062
2023	152	798	$1,626,828
2024	165	924	$1,705,600

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	86	$39,153
2016	N/R	11	$11,880
2017	N/R	N/R	N/R
2018	N/R	40	$4,709
2019	N/R	32	$4,089
2020	N/R	N/R	N/R
2021	N/R	14	$2,485
2022	N/R	36	$1,163
2023	N/R	39	$10,191
2024	N/R	73	$1,908

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	363	782	$110
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	563	1,329	$76
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	464	730	$15
36415	Insertion of needle into vein for collection of blood sample	686	2,337	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	681	2,307	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Promacta	Eltrombopag Olamine	34	1,260	$411,759
Imbruvica	Ibrutinib	23	666	$333,022
Calquence	Acalabrutinib Maleate	13	390	$199,905
Eliquis	Apixaban	88	4,330	$82,089
Xarelto	Rivaroxaban	60	2,160	$39,774

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	35	$1,312
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	24	$433
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$195	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Bruce Ira Kappel, MD?

Tedicare shows public-source Medicare data for Bruce Ira Kappel, MD (NPI 1336120211), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bruce Ira Kappel, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Bruce Ira Kappel, MD?

Bruce Ira Kappel, MD is linked to MEDICAL CARE OF QUEENS, PC (billing NPI 1225683840) in the available physician profile data.

Does Bruce Ira Kappel, MD have Open Payments data?

Bruce Ira Kappel, MD has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.